Skip to main content
Premium Trial:

Request an Annual Quote

New Products: CellMiner; BGI's PDXomics


The National Institutes of Health has updated its CellMiner software, available on the National Cancer Institute's website. CellMiner enables researchers and physicians to query data from 22,379 genes catalogued in the NCI-60 database and from 20,503 previously analyzed chemical compounds, including 102 US Food and Drug Administration-approved drugs. The software allows researchers to compare patterns of drug activity and gene expression to each other and also to patterns of interest. The software can also calculate correlations between genes and drug activity profiles and identify statistically significant correlations.

BGI has developed PDXomics, a filtering tool for cancer sequence data to classify reads of a tumor xenograft from reads from the host. According to BGI, the tool can be used to develop patient-derived xenografts.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.